HEPAREGENIX
HepaRegeniX is developing drugs for treating acute and chronic liver diseases that effectively restore the regenerative capacity of hepatocytes. The therapeutic concept is founded on research by Professor Lars Zender’s group at the University Hospital Tübingen, which identified mitogen-activated protein (MAP) kinase kinase 4 (MKK4) as a key regulator of liver regeneration. Work by Professor Zender’s team showed that using small RNA molecules to suppress MKK4 gene expression restored the regenerative capacity of hepatocytes, even in severely diseased livers. Founded in 2015, HepaRegeniX is developing small-molecule MKK4 inhibitors to treat liver disorders, potentially including nonalcoholic steatohepatitis.
HEPAREGENIX
Industry:
Biotechnology Health Care Life Science Therapeutics
Founded:
2015-01-01
Address:
Ulm, Baden-Wurttemberg, Germany
Country:
Germany
Website Url:
http://www.heparegenix.com
Total Employee:
1+
Status:
Active
Contact:
+49 731 2650428
Email Addresses:
[email protected]
Total Funding:
20 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Domain Not Resolving Apache Wordpress Plugins
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Ascenion GmbH
Ascenion GmbH investment in Series B - HepaRegeniX
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series B - HepaRegeniX
High-Tech Grunderfonds
High-Tech Grunderfonds investment in Series B - HepaRegeniX
Novo Holdings
Novo Holdings investment in Series B - HepaRegeniX
coparion
coparion investment in Series B - HepaRegeniX
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series A - HepaRegeniX
High-Tech Grunderfonds
High-Tech Grunderfonds investment in Series A - HepaRegeniX
Novo Holdings
Novo Holdings investment in Series A - HepaRegeniX
coparion
coparion investment in Series A - HepaRegeniX
Official Site Inspections
http://www.heparegenix.com
- Host name: 185.237.66.161
- IP address: 185.237.66.161
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "HepaRegeniX"
about – HepaRegeniX GmbH
Since its inception in 2017, HepaRegeniX has successfully discovered and developed several preclinical drug candidates for the treatment of acute and chronic liver diseases based on a …See details»
About us – HepaRegeniX GmbH
HepaRegeniX GmbH is a clinical stage company developing novel therapies for the treatment of acute and chronic liver diseases. Since its start in 2017, HepaRegeniX has successfully discovered and developed several drug …See details»
HepaRegeniX - Crunchbase Company Profile & Funding
HepaRegeniX is developing drugs for treating acute and chronic liver diseases that effectively restore the regenerative capacity of hepatocytes. The therapeutic concept is founded on research by Professor Lars Zender’s group at the …See details»
HepaRegenix Company Profile 2024: Valuation, …
Information on valuation, funding, cap tables, investors, and executives for HepaRegenix. Use the PitchBook Platform to explore the full profile.See details»
HepaRegeniX (HepaRegeniX GmbH)
HepaRegeniX GmbH erhält €9 Mio. in Serie-A-Finanzierungsrunde für die Entwicklung von Kinaseinhibitoren zur Behandlung akuter und chronischer Lebererkrankungen, High-Tech …See details»
HepaRegeniX - Funding, Financials, Valuation & Investors
HepaRegeniX is funded by 6 investors. Novo Holdings and HTGF | High-Tech Gruenderfonds are the most recent investors. Which investors participated in the most funding rounds?See details»
HepaRegeniX - Craft
HepaRegeniX has 5 employees across 2 locations and $21.21 m in total funding,. See insights on HepaRegeniX including office locations, competitors, revenue, financials, executives, …See details»
HepaRegeniX | VentureRadar
HepaRegeniX is a clinical stage company that specializes in developing a novel regenerative therapy for the treatment of acute and chronic liver diseases. The company has discovered …See details»
HepaRegeniX GmbH - Ulm, Germany - bionity.com
Oct 23, 2024 The biotech company HepaRegeniX, founded in 2017, starts clinical testing of the tolerability of its developed drug in volunteers.See details»
HepaRegeniX - Contacts, Employees, Board Members, Advisors
HepaRegeniX has 3 current employee profiles, including Chief Scientific Officer Birgit Jung. HepaRegeniX has 2 board members and advisors, including Emmanuelle Coutanceau.See details»
HepaRegeniX raises €15 million Series C round to advance clinical ...
Jul 15, 2024 HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapies for the treatment of acute and chronic liver diseases, announced the closing of a …See details»
HepaRegeniX CEO and Key Executive Team | Craft.co
HepaRegeniX's COO is Wolfgang Albrecht. Other executives include Birgit Jung, CSO. See the full leadership team at Craft.See details»
HepaRegeniX raises €15 million Series C round to advance
Tuebingen (Germany), July 10, 2024– HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, today …See details»
HepaRegeniX raises €15 million Series C round to advance clinical ...
Tuebingen (Germany), July 10, 2024 – HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, today …See details»
HepaRegeniX - VentureRadar
Since its inception in 2017, HepaRegeniX has successfully discovered and developed several preclinical drug candidates for the treatment of acute and chronic liver diseases based on a …See details»
HepaRegeniX - Tech Stack, Apps, Patents & Trademarks
Nov 1, 2024 HepaRegeniX uses 11 technology products and services including HTML5, Google Fonts, and Vimeo, according to G2 Stack. HepaRegeniX is actively using 3 technologies for its …See details»
HepaRegeniX raises €15 million Series C round to advance clinical ...
Jul 10, 2024 I look forward to working with the talented team at HepaRegeniX to advance the clinical development of HRX-215 through Phase II trials and beyond, with the ultimate goal of …See details»
HepaRegeniX GmbH (HepaRegeniX GmbH) - 药物管线_专利_临床 …
了解HepaRegeniX GmbH (HepaRegeniX GmbH)公司的药物管线，治疗领域，技术平台，以及它的1项临床试, 5篇新闻和3篇文献，疾病领域:肿瘤，技术平台:小分子化药，化学药，药物:HRX …See details»
Science - HepaRegeniX GmbH
HepaRegeniX aims at curing liver diseases by reversing the disease path through liver regeneration. Along this path, the company is actively developing novel therapies for the …See details»